$1.93
-0.06 (-3.02%)
Open$1.88
Previous Close$1.99
Day High$2.00
Day Low$1.81
52W High$29.28
52W Low$1.50
Volume—
Avg Volume1.45M
Market Cap4.32M
P/E Ratio—
EPS$-10.91
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+919.7% upside
Current
$1.93
$1.93
Target
$19.68
$19.68
$12.72
$19.68 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 403.3K | 2.01M | 478.0K |
| Net Income | -59,194,860 | -265,580,129 | -25,168 |
| Profit Margin | -14,677.7% | -13,943.8% | -5.3% |
| EBITDA | -55,511,870 | -262,892,704 | -28,783 |
| Free Cash Flow | — | — | -23,138 |
| Rev Growth | -79.9% | -79.9% | +3.1% |
| Debt/Equity | 2.46 | 2.46 | 0.11 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |